- Home
- LRMR vs ITIC Comparison
LRMR vs ITIC Comparison
Compare LRMR & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRMR | ITIC |
|---|---|---|
| Founded | N/A | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 444.2M |
| IPO Year | 2014 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LRMR | ITIC |
|---|---|---|
| Price | $3.46 | $242.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 19.4K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 4.43% |
| EPS Growth | N/A | ★ 13.02 |
| EPS | N/A | ★ 3.20 |
| Revenue | N/A | ★ $272,755,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,816.14 | N/A |
| P/E Ratio | ★ N/A | $76.38 |
| Revenue Growth | N/A | ★ 5.60 |
| 52 Week Low | $1.80 | $190.20 |
| 52 Week High | $6.42 | $288.98 |
Technical Indicators
Market Signals| Indicator | LRMR | ITIC |
|---|---|---|
| Relative Strength Index (RSI) | 35.07 | 54.98 |
| Support Level | $3.14 | $229.64 |
| Resistance Level | $3.78 | $247.37 |
| Average True Range (ATR) | 0.28 | 6.56 |
| MACD | -0.04 | 0.34 |
| Stochastic Oscillator | 22.79 | 83.22 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).